BioCryst (Nasdaq:BCRX) granted equity awards to nine new employees under Nasdaq Listing Rule 5635(c)(4). The awards include stock options for 33,950 shares and RSUs for 91,750 shares, granted July 1, 2026, with a $9.65 exercise price, four-year vesting, and 10-year option terms.
Loading...
Loading translation...
Positive
Options exercise price set at $9.65, equal to the grant-date closing price
Four-year vesting schedule may support employee retention and long-term focus
Negative
Equity awards for 33,950 options and 91,750 RSUs can increase share count over time
News Market Reaction – BCRX
+1.97%
+1.97%Session close to close
In the Jul 2 session, BCRX gained 1.97%, reflecting a mild positive market reaction.
The announcement details inducement grants for 33,950 stock options and 91,750 RSUs under Nasdaq Lis...
Analysis
The announcement details inducement grants for 33,950 stock options and 91,750 RSUs under Nasdaq Listing Rule 5635(c)(4), continuing BioCryst’s equity-based hiring practices. Investors may weigh this routine dilution against elevated short interest and the company’s ongoing strategic R&D refocus.
Key Figures
New employees granted:9 employeesStock options granted:33,950 sharesRSUs granted:91,750 shares+5 more
8 metrics
New employees granted9 employeesNew-hire inducement equity awards
Stock options granted33,950 sharesAggregate options for new hires
RSUs granted91,750 sharesAggregate restricted stock units for new hires
Option exercise price$9.65 per shareEqual to BioCryst closing price on July 1, 2026 grant date
Vesting schedule4 equal annual installmentsBeginning on first anniversary of July 1, 2026 grant date
Option term10 yearsTerm for each inducement stock option
Inducement plan referenceInducement Equity Incentive PlanGoverns options and RSUs granted
Listing ruleNasdaq Listing Rule 5635(c)(4)Basis for inducement equity grants
ISPOR 2026 real-world evidence on pediatric HAE burden and caregiver impact.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Over recent months, BioCryst’s share price has generally moved in line with the perceived tone of company news, with only one notable upside divergence on a data-focused event.
"The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4)."
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
restricted stock unitsfinancial
"and restricted stock units (RSUs) covering an aggregate of 91,750 shares"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
exercise pricefinancial
"The options have an exercise price of $9.65 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
equity incentive planfinancial
"subject to the terms and conditions of BioCryst’s Inducement Equity Incentive Plan"
An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.
RESEARCH TRIANGLE PARK, N.C., July 02, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted nine newly-hired employees stock options to purchase an aggregate of 33,950 shares, and restricted stock units (RSUs) covering an aggregate of 91,750 shares, of BioCryst common stock.The options and RSUs were granted as of July 1, 2026, as inducements material to each employee entering into employment with BioCryst.The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of $9.65 per share, which is equal to the closing price of BioCryst common stock on the grant date. The options and RSUs vest in four equal annual installments beginning on the one-year anniversary of the grant date, in each case subject to the new employee’s continued service with the company. Each stock option has a 10-year term. The options and RSUs are subject to the terms and conditions of BioCryst’s Inducement Equity Incentive Plan and a stock option agreement or restricted stock unit agreement, as applicable, covering the grant.
About BioCryst Pharmaceuticals
BioCryst is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (“HAE”) and other rare diseases, driven by its deep commitment to improving the lives of people living with these conditions. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of potential first-in-class or best-in-class oral small-molecule and injectable protein therapeutics for a range of rare diseases. For more information, please visit www.biocryst.com or follow us on LinkedIn.
BCRXW
Contact:
Investors: investorrelations@biocryst.com
Media: media@biocryst.com
FAQ
What equity awards did BioCryst (BCRX) announce on July 2, 2026?
BioCryst announced stock options for 33,950 shares and RSUs for 91,750 shares granted to nine new employees. According to BioCryst, these inducement awards were made under Nasdaq Listing Rule 5635(c)(4) effective July 1, 2026.
What is the exercise price of the new BioCryst (BCRX) stock options?
The new BioCryst stock options have a $9.65 exercise price per share. According to BioCryst, this equals the closing price of BioCryst common stock on the July 1, 2026 grant date for the inducement awards.
How do BioCryst (BCRX) inducement options and RSUs vest for new employees?
The options and RSUs vest in four equal annual installments starting one year after the grant date. According to BioCryst, continued service is required for vesting, and each stock option carries a 10-year term under the company’s inducement plan.
What does Nasdaq Listing Rule 5635(c)(4) mean for BioCryst (BCRX) inducement grants?
Nasdaq Listing Rule 5635(c)(4) allows equity awards as material inducements to employment without shareholder approval. According to BioCryst, the options and RSUs for new hires were granted in accordance with this rule under its Inducement Equity Incentive Plan.
How might the new BioCryst (BCRX) inducement grants affect shareholders?
If exercised or settled, the 33,950 options and 91,750 RSUs could add shares to BioCryst’s outstanding stock. According to BioCryst, these equity awards were granted to nine newly hired employees as employment inducements.
